MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock,...
$37,940K
Proceeds from exercise of
common warrants, net of...
$557K
Net cash provided by
financing activities
$38,497K
Increase (decrease) in
cash and cash...
$12,905K
Canceled cashflow
$25,592K
Non-cash lease expense
$1,089K
Prepaid expenses and
other current assets
-$483K
Depreciation and
amortization
$240K
Stock-based compensation
$96K
Net cash used in
operating activities
-$25,592K
Canceled cashflow
$1,908K
Net loss
-$25,967K
Operating lease liability
-$1,376K
Accounts payable,
accrued compensation,...
-$157K
Back
Back
Cash Flow
source: myfinsight.com
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)